Showing results (1271-1280 of 1,287) with videos related to

Sort By:
Pageof 129
Journal of the American Chemical Society|January 10, 2020
The Doping Mechanism of Halide Perovskite Unveiled by Alkaline Earth MetalsNga Phung, Roberto Félix, Daniele Meggiolaro, et al.
Nature Communications|July 10, 2021
Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleasesMoritz J Schmidt, Ashish Gupta, Christien Bednarski, et al.
BMC Cancer|May 9, 2023
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter studyCheng Huang, Xiao-Dong Zhu, Ying-Hao Shen, et al.
Liver Cancer|May 26, 2025
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 StudyZhaolong Pan, Dongming Liu, Junbo Cao, et al.
Scientific Reports|February 11, 2016
Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping ConsortiumGreg Finak, Marc Langweiler, Maria Jaimes, et al.
Liver Cancer|August 21, 2023
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter StudyBin Xu, San-Yuan Dong, Xue-Li Bai, et al.
The Oncologist|October 24, 2023
Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World StudyJianwei Liu, Xiaodong Zhu, Yangxun Pan, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2023
Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinomaZhengqing Lei, Weihu Ma, Anfeng Si, et al.
The New England Journal of Medicine|March 4, 2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic CholangiocarcinomaGuo-Ming Shi, Xiao-Yong Huang, Fei Liang, et al.
Nature|May 20, 2021
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primatesKiran Musunuru, Alexandra C Chadwick, Taiji Mizoguchi, et al.
Pageof 129